您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报 (医学版) ›› 2022, Vol. 60 ›› Issue (8): 44-49.doi: 10.6040/j.issn.1671-7554.0.2021.1380

• 临床医学 • 上一篇    下一篇

伽玛刀治疗81例肺癌脑转移瘤的疗效及预后因素

高中霞1,张铭1,樊明德1,谭晨阳1,王梦迪1,王超1,樊跃飞1,丁守銮2,王成伟1   

  1. 山东大学第二医院 1. 神经外科;2.基础医学研究所, 山东 济南 250033
  • 发布日期:2022-07-27
  • 通讯作者: 王成伟. E-mail: w6675778@126.com
  • 基金资助:
    山东大学横向课题(山东大学技术合同编号12681806)

Efficacy and prognostic factors of gamma knife in treating 81 cases of brain metastases from lung cancer

GAO Zhongxia1, ZHANG Ming1, FAN Mingde1, TAN Chenyang1, WANG Mengdi1, WANG Chao1, FAN Yuefei1, DING Shouluan2, WANG Chengwei1   

  1. 1. Department of Neurosurgery;
    2. Institute of Medical Sciences, The Second Hospital of Shandong University, Jinan 250033, Shandong, China
  • Published:2022-07-27

PDF (PC)

258

摘要： 目的 评估伽玛刀治疗肺癌脑转移瘤患者的疗效,分析影响生存预后的相关因素。 方法 选取2016年5月至2020年6月在我院神经外科接受伽玛刀治疗的81例肺癌脑转移瘤患者进行回顾性研究,随访后建立临床资料数据库。总生存期定义为从患者接受伽玛刀治疗到死亡或末次随访日期或第一次失访日期的时间间隔。使用 Kaplan-Meier法计算患者中位生存期、6个月、1年、2年的生存率,并绘制生存曲线。通过log-rank检验行单因素生存分析,检验各因素组间生存率的差异。采用Cox回归模型行多因素分析影响生存预后的不同因素。 结果 所有患者均获得随访,截至末次随访日期,81例患者中36例死亡(44.44%),伽玛刀治疗后的中位总生存期为23个月(95%CI=14~26)。6个月、1年、2年的总生存率分别为82.84%、63.53%、43.35%。结合单因素和多因素分析结果,转移灶总体积(HR=1.158,95%CI=1.079~1.242, P<0.001)、年龄(HR=2.666,95%CI=1.257~5.657,P=0.010 6)及边缘剂量(HR=0.392,95%CI=0.167-0.922,P=0.031 8)是影响生存的预后因素。结论 本项研究中接受伽玛刀治疗的肺癌脑转移瘤患者,生存率得到了提高、生存期得到了延长,收获了良好的疗效。转移灶总体积≥16 cm3、年龄≥70岁及给与边缘剂量<17Gy是预后不利因素,且差异有统计学意义(P<0.05)。

关键词: 伽玛刀, 立体定向放射外科, 脑转移瘤, 肺癌, 生存, 预后因素

Abstract: Objective To evaluate the efficacy of gamma knife in the treatment of brain metastases from lung cancer and to analyze factors affecting survival. Methods A total of 81 patients with brain metastases from lung cancer who received gamma knife treatment in the Neurosurgery Department of our hospital during May 2016 and June 2020 were selected for a retrospective study, and a database was established after follow-up. Overall survival was defined as the period from the time receiving gamma knife to the date of death or end of follow-up or the first loss of follow-up. The 6-month, 1-year and 2-year survival rate were calculated with Kaplan-Meier method, and the survival curve was plotted. The differences in survival rates were analyzed with Log-rank test. Factors affecting survival were analyzed with Cox multivariate regression. Results All patients were followed up, and 36 of the 81 patients died(44.44%)at the end of follow-up. The median overall survival was 23 months(95%CI: 14~26). The 6-month, 1-year and 2-year survival rate were 82.84%, 63.53% and 43.35%, respectively. The total volume of metastases(HR: 1.158, 95%CI: 1.079~1.242, P<0.001), age(HR: 2.666, 95%CI: 1.257~5.657, P=0.010 6), and marginal dose(HR: 0.392, 95%CI: 0.167~0.922, P=0.031 8) were factors affecting survival. Conclusions Patients with brain metastases from lung cancer who received gamma knife treatment in this study gained good efficacy, and their survival rate and survival time were improved. The total volume of metastases ≥16cm3, age ≥70 years, and marginal dose <17Gy were adverse prognostic factors(P<0.05).

Key words: Gamma knife, Stereotactic Radiosurgery, Brain metastases, Lung cancer, Survival, Prognostic factors

中图分类号: 

  • R651.1+9
[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin,2018, 68(6): 394-424.
[2] Smedby KE, Brandt L, Bäcklund ML, et al. Brain metastases admissions in Sweden between 1987 and 2006 [J]. Br J Cancer, 2009, 101(11): 1919-1924.
[3] Berghoff AS, Schur S, Füreder LM, et al. Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers [J]. ESMO Open, 2016, 1(2): e000024. doi: 10.1136/esmoopen-2015-000024.
[4] Soffietti R, Kocher M, Abacioglu UM, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results [J]. J Clin Oncol, 2013, 31(1): 65-72.
[5] 赵东海, 杜汉强, 王嘉嘉, 等. 伽玛刀治疗对脑转移瘤病人认知功能及生活质量影响的研究[J]. 中国微侵袭神经外科杂志, 2020, 25(5): 205-208. ZHAO Donghai, DU Hanqiang, WANG Jiajia, Effects of gamma knife treatment on cognitive function and quality of life in patients with brain metastases [J]. Chinese Journal of Minimally Invasive Neurosurgery,2020, 25(5): 205-208.
[6] 王嘉嘉, 赵东海, 梁军潮. 脑转移瘤的伽马刀治疗新进展[J]. 广东医学, 2019, 40(1): 24-26.
[7] Berghoff AS, Preusser M. New developments in brain metastases [J]. Ther Adv Neurol Disord, 2018, 11: 1756286418785502. doi: 10.1177/1756286418785502.
[8] Shen H, Deng G, Chen Q, et al. The incidence, risk factors and predictive nomograms for early death of lung cancer with synchronous brain metastasis: a retrospective study in the SEER database [J]. BMC Cancer, 2021, 21(1): 825.
[9] Soffietti R, Abacioglu U, Baumert B, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology(EANO)[J]. Neuro Oncol, 2017, 19(2): 162-174.
[10] Protopapa M, Kouloulias V, Nikoloudi S, et al. From Whole-Brain Radiotherapy to Immunotherapy: A Multidisciplinary Approach for Patients with Brain Metastases from NSCLC [J]. J Oncol, 2019, 2019: 3267409. doi: 10.1155/2019/3267409.
[11] Spencer K, Hall A, Jain P. Brain metastases [J]. Clin Med(Lond), 2014, 14(5): 535-537.
[12] 董耀东, 魏薇, 马秀岚. 立体放射治疗技术在听神经瘤治疗中的应用进展[J]. 中华耳科学杂志, 2020, 18(1): 25-32. DONG Yaodong, WEI Wei, MA Xiulan. Progress in Application of Stereotactic Radiosurgery in Treatment of Acoustic Neuroma [J]. Chinese Journal of Otology, 2020, 18(1): 25-32.
[13] Soliman H, Das S, Larson DA, et al. Stereotactic radiosurgery(SRS)in the modern management of patients with brain metastase s[J]. Oncotarget, 2016, 7(11): 12318-2330.
[14] Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy(QUARTZ): results from a phase 3, non-inferiority, randomised trial [J]. Lancet, 2016, 388(10055): 2004-2014.
[15] Gong X, Zhou D, Liang S, et al. Analyses of prognostic factors in cases of non-small cell lung cancer with multiple brain metastases [J]. Onco Targets Ther, 2016, 9: 977-983. doi: 10.2147/OTT.S94524.
[16] Fulop T, Kotb R, Fortin CF, et al. Potential role of immunosenescence in cancer development [J]. Ann N Y Acad Sci, 2010, 197: 158-165. doi: 10.1111/j.1749-6632.2009.05370.x.
[17] Gu Y, Zhang J, Zhou Z, et al. Metastasis Patterns and Prognosis of Octogenarians with NSCLC: A Population-based Study [J]. Aging Dis, 2020, 11(1): 82-92.
[18] Venuta F, Diso D, Onorati I, et al. Lung cancer in elderly patients [J]. J Thorac Dis, 2016,(Suppl 11): S908-S914.
[19] 祁艺, 王宏伟, 张国荣. 伽玛刀治疗肺癌脑转移瘤的疗效及影响生存时间和预后的相关因素分析[J]. 脑与神经疾病杂志, 2016, 24(11): 709-713. QI Yi, WANG Hongwei, ZHANG Guorong. The curative effect, survival time and prognostic analysis for brain metastasis from lung cancer after Gamma-knife treatment [J]. Journal of Brain and Nervous Diseases, 2016, 24(11): 709-713.
[20] Weltman E, Salvajoli JV, Brandt RA, et al. Radiosurgery for brain metastases: a score index for predicting prognosis [J]. Int J Radiat Oncol Biol Phys, 2000, 46(5): 1155-1161.
[21] Zabel A, Milker-Zabel S, Thilmann C, et al. Treatment of brain metastases in patients with non-small cell lung cancer(NSCLC)by stereotactic linac-based radiosurgery: prognostic factors [J]. Lung Cancer, 2002, 37(1): 87-94.
[22] Routman DM, Bian SX, Diao K, et al. The growing importance of lesion volume as a prognostic factor in patients with multiple brain metastases treated with stereotactic radiosurgery [J]. Cancer Med, 2018, 7(3): 757-764.
[23] Chang WS, Kim HY, Chang JW, et al. Analysis of radiosurgical results in patients with brain metastases according to the number of brain lesions: is stereotactic radiosurgery effective for multiple brain metastases? [J]. J Neurosurg, 2010, 113 Suppl: 73-78. doi: 10.3171/2010.8.GKS10994.
[24] Likhacheva A, Pinnix CC, Parikh NR, et al. Predictors of Survival in Contemporary Practice After Initial Radiosurgery for Brain Metastases [J]. Int J Radiat Oncol Biol Phys, 2013, 85(3): 656-661.
[25] Cho KR, Lee MH, Kong DS, et al. Outcome of gamma knife radiosurgery for metastatic brain tumors derived from non-small cell lung cancer [J]. J Neurooncol, 2015, 125(2): 331-338.
[26] Bowden GN, Kim JO, Faramand A, et al. Clinical dose profile of Gamma Knife stereotactic radiosurgery for extensive brain metastases [J]. J Neurosurg, 2020, 134(5): 1430-1434.
[27] Redmond KJ, Gui C, Benedict S, et al. Tumor Control Probability of Radiosurgery and Fractionated Stereotactic Radiosurgery for Brain Metastases [J]. Int J Radiat Oncol Biol Phys, 2021, 110(1): 53-67.
[1] 吴瑞芳,李长忠. 女性生育力保护的现状与进展[J]. 山东大学学报 (医学版), 2022, 60(9): 1-7.
[2] 韩靖,贾春玲. 肺癌患者胸外手术前治疗牙周基础疾病对预防术后肺炎发生的效果评价[J]. 山东大学学报 (医学版), 2022, 60(9): 113-118.
[3] 秦静,杨飞,陈谦,夏涵岱,刘延国,王秀问. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报 (医学版), 2022, 60(7): 74-82.
[4] 王福立,孙银萍,秦杰,荣建胜. DC-CIK细胞联合EGFR-TKI治疗35例老年晚期EGFR突变肺癌的效果[J]. 山东大学学报 (医学版), 2022, 60(7): 110-117.
[5] 董晓倩,李冠江,许倩倩,许洪伟. 66例经ERCP联合熊去氧胆酸治疗老年胆总管并胆囊结石患者与其他疗法比较[J]. 山东大学学报 (医学版), 2022, 60(5): 59-66.
[6] 陈兆波,方敏,薛浩然,刘春艳. 去泛素化酶USP35促进非小细胞肺癌细胞迁移和侵袭[J]. 山东大学学报 (医学版), 2022, 60(4): 30-37.
[7] 高会江,魏煜程. 微创袖式肺叶切除手术:免疫治疗时代的机遇和挑战[J]. 山东大学学报 (医学版), 2022, 60(11): 23-27.
[8] 彭岳,刘雷,李原,别凤龙,周博伦,李润泽,冀瑛,白广宇,谭锋维,高禹舜,牟巨伟,薛奇,邱斌,高树庚. 解剖性部分肺叶切除术及围术期加速康复外科的临床综合应用[J]. 山东大学学报 (医学版), 2022, 60(11): 44-53.
[9] 高树庚. 加速康复外科在肺癌围术期管理中的应用[J]. 山东大学学报 (医学版), 2022, 60(11): 1-10.
[10] 韩丁培,严越,曹羽钦,孙昕,胡琰霞,汪敏娴,罗艳,施咏梅,谢青,杭钧彪,李鹤成. 加速康复外科理念在胸外科临床实践指导的瑞金医院专家共识[J]. 山东大学学报 (医学版), 2022, 60(11): 11-16.
[11] 刘会宁,彭军,任迎春,杨光,王文豪,刘金锋,田勍. 34例胸腔镜下肺楔形切除与21例肺段切除对位于肺段P区的ⅠA1期非小细胞肺癌治疗比较[J]. 山东大学学报 (医学版), 2022, 60(11): 38-43.
[12] 时萧寒,李华玉,李峰. 接受Stupp方案治疗的老年胶质母细胞瘤患者预后的影响因素[J]. 山东大学学报 (医学版), 2022, 60(10): 42-48.
[13] 丁子琛,王浩桦,周立雯,丛慧文,李承圣,包绮晗,杨毅,王廉源,王素珍,石福艳. 基于贝叶斯累加回归树模型的非小细胞肺癌患者个性化疗效研究[J]. 山东大学学报 (医学版), 2022, 60(10): 92-98.
[14] 于金明,颜薇薇,陈大卫. 肺癌放射免疫新实践[J]. 山东大学学报 (医学版), 2021, 59(9): 1-8.
[15] 孙庆杰,张怡莎,管尚慧,凤志慧. 丙戊酸对134例放疗神经胶质瘤患者预后生存和肿瘤复发的影响[J]. 山东大学学报 (医学版), 2021, 59(8): 80-85.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 马青源,蒲沛东,韩飞,王超,朱洲均,王维山,史晨辉. miR-27b-3p调控SMAD1对骨肉瘤细胞增殖、迁移和侵袭作用的影响[J]. 山东大学学报 (医学版), 2020, 1(7): 32 -37 .
[2] 索东阳,申飞,郭皓,刘力畅,杨惠敏,杨向东. Tim-3在药物性急性肾损伤动物模型中的表达及作用机制[J]. 山东大学学报 (医学版), 2020, 1(7): 1 -6 .
[3] 张宝文,雷香丽,李瑾娜,罗湘俊,邹容. miR-21-5p靶向调控TIMP3抑制2型糖尿病肾病小鼠肾脏系膜细胞增殖及细胞外基质堆积[J]. 山东大学学报 (医学版), 2020, 1(7): 7 -14 .
[4] 付洁琦,张曼,张晓璐,李卉,陈红. Toll样受体4抑制过氧化物酶体增殖物激活受体γ加重血脂蓄积的分子机制[J]. 山东大学学报 (医学版), 2020, 1(7): 24 -31 .
[5] 丁祥云,于清梅,张文芳,庄园,郝晶. 胰岛素样生长因子II在84例多囊卵巢综合征患者颗粒细胞中的表达和促排卵结局的相关性[J]. 山东大学学报 (医学版), 2020, 1(7): 60 -66 .
[6] 徐玉香,刘煜东,张蓬,段瑞生. 101例脑小血管病患者脑微出血危险因素的回顾性分析[J]. 山东大学学报 (医学版), 2020, 1(7): 67 -71 .
[7] 郭志华,赵大庆,邢园,王薇,梁乐平,杨静,赵倩倩. Ⅰ期端端吻合术治疗重度颈段气管狭窄临床分析[J]. 山东大学学报 (医学版), 2020, 1(7): 72 -76 .
[8] 肖娟,肖强,丛伟,李婷,丁守銮,张媛,邵纯纯,吴梅,刘佳宁,贾红英. 两种甲状腺超声数据报告系统诊断效能的比较[J]. 山东大学学报 (医学版), 2020, 1(7): 53 -59 .
[9] 吕龙飞,李林,李树海,亓磊,鲁铭,程传乐,田辉. 腔镜下细针导管空肠造瘘在微创McKeown食管癌切除术中的应用[J]. 山东大学学报 (医学版), 2020, 1(7): 77 -81 .
[10] 张娟,张璐嘉,肖伟,李顺平. 住院医师规范化培训学员压力知觉与留职意愿及影响因素[J]. 山东大学学报 (医学版), 2020, 1(7): 108 -114 .
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发